Author | Millie Leung, MD

Articles

A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor

April 01, 2002

ByN. Simon Tchekmedyian, MD, FACP

Kalust Ucar, MD, FACP

Eleonor Quan, MD

Howard Cheng, MD

Millie Leung, MD

Ghassan Al-jazayrly, MD

And Andr&, 233; Liem, MD

Among the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.